Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood markers may reveal hidden risks in obesity

NCT ID NCT07431593

Knowledge-focused Sponsor: University of Rijeka Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at two blood inflammation markers, SII and SIRI, to see if they can help predict metabolic problems like insulin resistance and fatty liver in people who are overweight or have obesity. Researchers will follow 200 adults for up to 3 years, tracking their diet, lab results, and response to treatments. The goal is to find a simple, affordable way to identify those at higher risk and guide better care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adults with overweight or obesity who are receiving obesity management at outpatient obesity clinics. Eligible participants are 18 years or older and have a BMI between 25.0-29.9 kg/m² (overweight) or BMI ≥ 30 kg/m² (obesity). All participants must be able to attend scheduled clinical visits and must provide written informed consent.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Age ≥ 18 years * BMI 25.0-29.9 kg/m² (overweight) or BMI ≥ 30 kg/m² (obesity) * Ability to attend scheduled clinical visits * Willingness to provide informed consent Exclusion Criteria * Pregnancy or breastfeeding * Use of immunosuppressive therapy * Active infection * Inflammatory disease * Malignancy * Acute illness affecting immune parameters * Conditions interfering with study participation (as assessed by the investigator) * Known hematologic disorders affecting leukocyte or platelet counts * Chronic inflammatory diseases requiring systemic therapy * Recent major surgery (within the last 3 months) * Any condition that could confound the relationship between SII/SIRI and obesity-driven inflammation, such as immune disorders

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Inflammation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome Inflammation inflammatory disease metabolic syndrome X Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Inflammation Metabolic syndrome Overweight and obesity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • General Hospital Varaždin

    RECRUITING

    Varaždin, Croatia

More trials for these conditions

Other studies related to the condition(s) this trial covers.